Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen

Reducing the synthesis of apoC-III reduces fasting triglycerides in individuals lacking lipoprotein lipase activity. Recently, Stroes et al. published a phase 3 trial on the effects of olezarsen, a third-generation antisense oligonucleotide that blocks apoC-III mRNA, on triglycerides and risk of acu...

Full description

Saved in:

Bibliographic Details
Published in:	Med (New York, N.Y. : Online) Vol. 5; no. 6; p. 493
Main Authors:	Valdivielso, Pedro, Coca Prieto, Inmaculada
Format:	Journal Article
Language:	English
Published:	United States 14-06-2024
Subjects:	Apolipoprotein C-III - blood Apolipoprotein C-III - genetics Benzimidazoles Humans Hyperlipoproteinemia Type I - blood Hyperlipoproteinemia Type I - genetics Oligonucleotides - pharmacology Oligonucleotides - therapeutic use Oligonucleotides, Antisense - pharmacology Oligonucleotides, Antisense - therapeutic use Pancreatitis - genetics Triglycerides - blood
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Reducing the synthesis of apoC-III reduces fasting triglycerides in individuals lacking lipoprotein lipase activity. Recently, Stroes et al. published a phase 3 trial on the effects of olezarsen, a third-generation antisense oligonucleotide that blocks apoC-III mRNA, on triglycerides and risk of acute pancreatitis.
ISSN:	2666-6340
DOI:	10.1016/j.medj.2024.05.004